Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IDEAYA Biosciences, Inc. (IDYA)

IDEAYA Biosciences shareholders elect three directors, ratify auditor at June 16 meeting

Neutral Impact 3 of 5 shareholder Written later

At its June 16, 2026 annual meeting, IDEAYA Biosciences stockholders elected three Class I directors, ratified PricewaterhouseCoopers LLP as auditor for 2026, and approved executive compensation in a non-binding vote. The same day, the board named Yujiro S. Hata chairman and Terry Rosen, Ph.D., lead independent director, which sets the board's leadership structure.

Key points

  • Yujiro S. Hata received 70,546,418 votes for and 2,470,077 withheld; M. Garret Hampton, Ph.D., received 56,718,637 for and 16,297,858 withheld
  • PricewaterhouseCoopers LLP ratified: 82,579,758 for, 141,240 against, 384,840 abstentions
  • Advisory say-on-pay vote: 64,269,756 for, 8,349,131 against, 397,608 abstentions
  • Effective June 16, 2026, Hata became Chairman and Terry Rosen, Ph.D., became Lead Independent Director

The filing

CompanyIDEAYA Biosciences, Inc. (IDYA)
Form8-K, current report
Filed with the SECJun 23, 2026, 4:05 PM ET
Accession number0001193125-26-279427

Items reported: 5.07 Shareholder Vote Results8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.